Evaluating oral noncombustible potential reduced exposure products for smokers

Nicotine and Tobacco Research

Volumn 12, Issue 4, 2010, Pages 336-343

  Blank, Melissa D ^a   Eissenberg, Thomas ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; CARCINOGEN; COTININE; NICOTINE; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; 4-(N-METHYL-N-NITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE; NITROSAMINE;

ADULT; ARTICLE; CIGARETTE SMOKING; CLINICAL ARTICLE; EXPIRED AIR; FEMALE; HUMAN; MALE; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; WITHDRAWAL SYNDROME; ADOLESCENT; CLINICAL TRIAL; METABOLISM; METHODOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; SMOKELESS TOBACCO; SMOKING CESSATION; URINE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CARBON MONOXIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINE; NITROSAMINES; SMOKING CESSATION; TOBACCO, SMOKELESS; YOUNG ADULT;

EID: 77953954536     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntq003     Document Type: Article

References (32)

1. Acosta, M.C., Buchhalter, A.R., Breland, A.B., Hamilton, D.C.P., &Eissenberg, T. (2004). Urine cotinine as an index of smoking status in abstinent smokers: Comparison of GC/MS with immunoassay test strip. Nicotine &Tobacco Research, 6, 615-620.
2. Blank, M.D., Sams, C., Weaver, M.F., &Eissenberg, T. (2008). Nicotine delivery, cardiovascular profile, and subjective effects of an oral tobacco product for smokers. Nicotine &Tobacco Research, 10, 417-421.
3. Bolliger, C.T., Zellweger, J.P., Danielsson, T., van Biljon, X., Robidou, A., Westin, A., et al. (2002). Influence of long-term smoking reduction on health risk markers and quality of life. Nicotine &Tobacco Research, 4, 433-439.
4. Breland, A.B., Buchhalter, A.R., Evans, S.E., &Eissenberg, T. (2002). Evaluating acute effects of potential reduced-exposure products for smokers: Clinical laboratory methodology. Nicotine &Tobacco Research, 4, S131-S140.
5. Breland, A.B., Kleykamp, B.A., &Eissenberg, T. (2006). Clinical laboratory evaluation of potential reduced exposure products for smokers. Nicotine &Tobacco Research, 8, 727-738.
6. Cobb, C.O., Weaver, M.F., &Eissenberg, T. (2009). Evaluating the acute effects of oral, non-combustible potential reduced exposure products marketed to smokers. Tobacco Control. Published online 2 April; doi:10.1136/tc.2008.028993.
7. Evans, S.E., Blank, M., Sams, C., Weaver, M.F., &Eissenberg, T. (2006). Transdermal nicotine-induced tobacco abstinence symptoms suppression: Nicotine dose and smokers' gender. Experimental and Clinical Psychopharmacology, 14, 121-135.
8. Federal Trade Commission. (2000). Tar, nicotine, and carbon monoxide of the smoke of 1294 varieties of domestic cigarettes for the year 1998. Washington, DC.
9. Gray, J.N., Breland, A.B., Weaver, M.F., &Eissenberg, T. (2008). Potential reduced exposure products (PREPs) for smokeless tobacco users: Clinical evaluation methodology. Nicotine &Tobacco Research, 10, 1441-1448.
10. Hatsukami, D.K., Ebbert, J.O., Feuer, R.M., Stepanov, I., &Hecht, S.S. (2007). Changing smokeless tobacco products new tobacco-delivery systems. American Journal of Preventive Medicine, 33(Suppl. 6), S368-S378.
11. Hatsukami, D.K., Giovino, G.A., Eissenberg, T., Clark, P.I., Lawrence, D., &Leischow, S. (2005). Methods to assess potential reduced exposure products. Nicotine &Tobacco Research, 7, 827-844.
12. Hatsukami, D.K., Lemmonds, C., Zhang, Y., Murphy, S.E., Le, C., Carmella, S.G., et al. (2004). Evaluation of carcinogen exposure in people who used " reduced exposure" tobacco products. Journal of the National Cancer Institute, 96, 844-852.
13. Heatherton, T.F., Kozlowski, L.T., Frecker, R.C., &Fagerström, K. O. (1991). The Fagerstrom Test for Nicotine Dependence: A revision of the Fagerstrom Tolerance Questionnaire. British Journal of Addiction, 86, 1119-1127.
14. Hughes, J.R., &Hatsukami, D. (1986). Signs and symptoms of tobacco withdrawal. Archives of General Psychiatry, 43, 289-294.
15. Hughes, J.R., &Keely, J.P. (2004). The effect of a novel smoking system-Accord-on ongoing smoking and toxin exposure. Nicotine &Tobacco Research, 6, 1021-1027.
16. Huynh, H., &Feldt, L.S. (1976). Estimation of the box correction for degrees of freedom from sample data in randomized block and split-plot designs. Journal of Educational Statistics, 1, 69-82.
17. Keppel, G. (1991). Design and analysis, a researcher's handbook. Englewood Cliffs, NJ: Prentice Hall.
18. Kotlyar, M., Mendoza-Baumgart, M.I., Li, Z.Z., Pentel, P.R., Barnett, B.C., Feuer, R.M., et al. (2007). Nicotine pharmacokinetics and subjective effects of three potential reduced exposure products, moist snuff and nicotine lozenge. Tobacco Control, 16, 138-142.
19. Lakier, J.B. (1992). Smoking and cardiovascular disease. American Journal of Medicine, 93, 8S-12S.
20. Lewin, F., Norell, S.E., Johansson, H., Gustavsson, P., Wennerberg, J., Bjorklund, A., et al. (1998). Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck. A population based case-referent study in Sweden. Cancer, 82, 1367-1375.
21. Naidong, W., Shou, W., Chen, Y-L, &Jiang, X. (2001). Novel liquid chromatographic-tandem mass spectrometric methods using silica columns and aqueous-organic mobile phases for quantitative analysis of polar ionic analytes in biological fluids. Journal of Chromatography B, Biomedical Sciences and Applications, 754, 387-399.
22. National Cancer Institute. (2001). Risks associated with smoking cigarettes with low tar machine-measured yield of tar and nicotine: A report of the NCI expert committee. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health. Retrieved 11 August 2009, from http://cancercontrol.cancer.gov/tcrb/monographs/13/m13_complete.pdf.
23. Pullan, R.D., Rhodes, J., Ganesh, S., Mani, V., Morris, J.S., Williams, G.T., et al. (1994). Transdermal nicotine for active ulcerative colitis. New England Journal of Medicine, 330, 811-815.
24. Roethig, H.J., Zedler, B.K., Kinser, R.D., Feng, S., Nelson, B.L., &Lian, Q. (2007). Short-term clinical exposure evaluation of a second generation electrically heated cigarette smoking system. Journal of Clinical Pharmacology, 47, 518-530.
25. Schildt, E-B., Eriksson, M., Hardell, L., &Magnuson, A. (1998). Oral snuff, smoking habits and alcohol consumption in relation to oral cancer in a Swedish case-control study. International Journal of Cancer, 77, 341-346.
26. Stepanov, I., Jensen, J., Hatsukami, D., &Hecht, S.S. (2008). New and traditional smokeless tobacco: Comparison of toxcicant and carcinogen levels. Nicotine &Tobacco Research, 10, 1773-1782.
27. Stratton, K., Shetty, P., Wallace, R., &Bondurant, S., (Eds.). (2001). Clearing the smoke: The science base for tobacco harm reduction, committee to assess the science base for tobacco harm reduction, board on health promotion and disease prevention. Washington, DC: National Academy Press.
28. Thun, M.J., &Heath, C.W., Jr. (1997). Changes in from mortality in smoking from two American Cancer Society prospective studies since 1959. Preventative Medicine, 26, 422-426.
29. Tiffany, S.T., &Drobes, D.J. (1991). The development and initial validation of a questionnaire on smoking urges. British Journal of Addiction, 86, 1467-1476.
30. United States Department of Health and Human Services. (2004). The health consequences of smoking: A report of the surgeon general. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.
31. Warner, K.E. (2002). Tobacco harm reduction: Promise and perils. Nicotine &Tobacco Research, 4, S61-S71.
32. Wogan, G.N., Hecht, S.S., Felton, J.S., Conney, A.H., &Loeb, L.A. (2004). Environmental and chemical carcinogenesis. Seminars in Cancer Biology, 14, 473-486.